本公司及董事会全体成员保证公告内容的真实、准确和完整，没 有虚假记载、误导性陈述或重大遗漏。 一、被实施其他风险警示暨可能被实施退市风险警示的相关情况 公司董事会对众华出具无法表示意见的内部控制审计报告涉及的事项高度 重视，积极采取相应的措施，尽快消除相关事项及其影响。结合公司的实际情况， 公司已采取和拟采取的措施如下： 证券代码：300326 证券简称：ST 凯利 公告编号：2025-084 上海凯利泰医疗科技股份有限公司 上海凯利泰医疗科技股份有限公司（以下简称"公司"）2024年度财务报告 内部控制被众华会计师事务所（特殊普通合伙）（以下简称"众华"）出具了无 法表示意见的审计报告。根据《深圳证券交易所创业板股票上市规则》（以下简 称"《创业板股票上市规则》"）第9.4条第（四）项规定，公司出现"（四） 最近一个会计年度财务报告内部控制被出具无法表示意见或者否定意见的审计 报告，或者未按照规定披露财务报告内部控制审计报告"的情形，公司股票交易 被深圳证券交易所实施其他风险警示；根据《深圳证券交易所创业板股票上市规 则》第 10.4.4 条第（五）项规定，上市公司出现"首个会计年度财务报告内部 控制被出具 ...

浙江拱东医疗器械股份有限公司 2025 年半年度报告 公司代码：605369 公司简称：拱东医疗 浙江拱东医疗器械股份有限公司 浙江拱东医疗器械股份有限公司 2025 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确 性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人施慧勇、主管会计工作负责人朱勇及会计机构负责人（会计主管人员）尤志仁 声明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告中所涉及的经营计划、发展战略、未来计划等前瞻性陈述不构成公司对投资者的实质 承诺，投资者及相关人士均应当对此保持足够的风险认识，并且应当理解计划、预测与承诺之间 的差异。 七、 是否存在被控股股东及其他关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况 否 九、 是否存在半数以上董事无法保证公司所披露半年度报告 ...

Core Viewpoint - Zhejiang Gongdong Medical Devices Co., Ltd. reported a slight increase in revenue but a significant decline in profit for the first half of 2025, indicating potential challenges in operational efficiency and profitability [1]. Financial Summary - Total assets at the end of the reporting period reached approximately 2.12 billion RMB, an increase of 8.73% compared to the end of the previous year [1]. - Operating revenue for the period was approximately 556.92 million RMB, reflecting a modest increase of 0.58% year-on-year [1]. - Total profit for the period was approximately 55.86 million RMB, showing a substantial decrease of 47.86% compared to the same period last year [1]. - Net profit attributable to shareholders was significantly lower, with a basic earnings per share of 0.23 RMB, down 46.51% from 0.43 RMB in the previous year [1]. - The weighted average return on net assets decreased to 2.91%, down 2.76 percentage points from the previous year [1]. Shareholder Information - The largest shareholder, Shi Huiyong, holds 50.27% of the shares, followed by Shi Yibei with 7.47% [2]. - Other notable shareholders include Taizhou Jinch Investment Management Partnership and several individuals with smaller stakes [2]. - There are noted relationships among major shareholders, indicating potential unified actions in decision-making [3].

Group 1 - The third meeting of the supervisory board of Zhejiang Gongdong Medical Instrument Co., Ltd. was held on August 25, 2025, with all three supervisors present, confirming the legality and validity of the meeting [1][2] - The supervisory board approved the proposal regarding the company's 2025 semi-annual report and its summary, with a unanimous vote of 3 in favor [1][2] - The supervisory board also approved the proposal to cancel the supervisory board and amend the company's articles of association, which will require further approval from the shareholders' meeting [2]

Core Viewpoint - The Shanghai Kangdelai Enterprise Development Group Co., Ltd. is preparing for its shareholder meeting scheduled for September 11, 2025, focusing on maintaining investor rights and ensuring meeting efficiency [1][2]. Meeting Procedures - The shareholder meeting will utilize a combination of on-site and online voting methods, allowing all registered shareholders to exercise their voting rights through the Shanghai Stock Exchange system [2]. - All resolutions will be voted on using written ballots, with shareholders required to select "agree," "disagree," or "abstain" for each resolution [2][3]. - Shareholders must register in advance to speak at the meeting, with each speaker limited to five minutes and required to introduce themselves [2][3]. Agenda Items - The meeting agenda includes reading the meeting rules, presenting the resolutions, appointing vote counters, conducting on-site voting, announcing results, and reading the legal opinion from the witnessing lawyer [3][4]. Proposal for Change of Auditor - The company proposes to change its auditing firm from Lixin Certified Public Accountants to Lixin Zhonglian Certified Public Accountants for the 2025 fiscal year to enhance audit objectivity and meet business development needs [4]. - Lixin Zhonglian was established on October 31, 2013, and has 48 partners and 287 registered accountants, with a total audited revenue of 315.55 million yuan in 2024 [4][5]. - The proposed audit fee for 2025 is 2.2 million yuan, which includes 1.7 million yuan for annual report auditing and 500,000 yuan for internal control auditing [6].

Meeting Information - The first extraordinary general meeting of shareholders for 2025 will be held on September 18, 2025, at 14:00 [1] - The meeting will take place in the conference room on the third floor of Zhejiang Gongdong Medical Instrument Co., Ltd. [1] - Shareholders can vote through the Shanghai Stock Exchange's online voting system from 9:15 to 15:00 on the day of the meeting [1][3] Voting Procedures - Shareholders can participate in voting via both on-site and online methods [3][4] - For online voting, shareholders must complete identity verification if logging in for the first time [3] - Shareholders with multiple accounts can vote through any of their accounts, but the first voting result will be considered valid [4] Attendance and Registration - Shareholders registered with China Securities Depository and Clearing Corporation Limited by the close of trading on September 10, 2025, are eligible to attend [4] - Shareholders can appoint representatives to attend the meeting, who must present valid identification and authorization documents [5][6] Proxy Voting - Proxy voting requires a written authorization letter, which must include specific details such as the proxy's name and voting instructions [5][8] - The proxy must present the authorization letter and identification at the meeting [5][6] Contact Information - The company has provided contact details for inquiries regarding the meeting [6]

浙江拱东医疗器械股份有限公司 （浙江省台州市黄岩区北院大道10号） 会议资料 目 录 浙江拱东医疗器械股份有限公司 汇总现场会议和网络投票表决情况。 六、宣布决议和法律意见 为维护股东的合法权益，确保会议秩序和议事效率，根据《公司法》《公司 章程》及《公司股东大会议事规则》等有关规定，特制定本次会议须知： 详见本次会议通知），经律师验证后办理签到手续并领取会议资料，除上述人员 和公司董监高、见证律师及董事会邀请的人员外，其他无关人员不得入场。在会 议主持人宣布会议开始时，会议登记终止。 等各项权利，会议进行中要求发言的股东或者股东代理人，应当先向会议主持人 提出申请，并经主持人同意后方可发言。 得超过 3 分钟。主持人可安排公司相关人员回答股东问题，与本次股东大会议题 无关或将泄露公司商业秘密或损害公司、股东共同利益的，大会主持人或其指定 的有关人员有权拒绝回答。议案表决开始后，大会将不再安排股东发言。 公布表决结果。 照及录像。会议期间，未经公司允许不得私自拍照、录制视频、音频对外发布， 造成信息泄露者，依法承担相关法律责任。对扰乱会议的正常秩序和会议议程、 侵犯公司和其他股东或股东代理人的合法权益的行为， ...

免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每经AI快讯，可孚医疗（SZ 301087，收盘价：40.5元）8月25日晚间发布半年度业绩报告称，2025年上 半年营业收入约14.96亿元，同比减少4.03%；归属于上市公司股东的净利润约1.67亿元，同比减少 9.51%；基本每股收益0.82元，同比减少9.89%。 每日经济新闻 每经头条（nbdtoutiao）——租下2.5万亩"试验田"，兽医学博士在非洲种粮：首季亩产250斤，打算扩至 10万亩，月薪1~2万元招人 （记者 张喜威） ...

Core Viewpoint - DIRUI Medical Technology Co., Ltd. reported a significant decline in revenue and net profit for the first half of 2025, indicating challenges in the medical device industry, particularly in the in vitro diagnostics (IVD) sector, amidst increasing competition and regulatory pressures [4][6]. Company Overview and Financial Indicators - The company’s stock code is 300396, and it is listed on the Shenzhen Stock Exchange [4]. - For the reporting period, the company generated revenue of approximately ¥350.69 million, a decrease of 60.07% compared to the same period in 2024 [4]. - The net profit attributable to shareholders was a loss of approximately ¥28.31 million, a decline of 117.13% year-on-year [4]. - The company plans not to distribute cash dividends or issue bonus shares [4]. Industry Analysis - The medical device industry, particularly the IVD sector, is experiencing a transformation driven by AI technology and increasing domestic demand [6]. - The IVD market in China is projected to grow to ¥288.15 billion by 2030, capturing 33.2% of the global market share [6]. - The industry is facing challenges due to macroeconomic conditions, healthcare cost control, and intensified centralized procurement, which may slow overall growth in 2024 [6]. Business Operations - The company focuses on the research, production, marketing, and service of medical testing instruments and related reagents, covering a wide range of diagnostic applications [6][10]. - DIRUI Medical employs a sales model that emphasizes distribution partnerships while also engaging in direct sales [10]. - The company has made significant investments in R&D, aiming to enhance product quality and expand its market presence both domestically and internationally [10]. Regulatory Environment - Recent government policies aim to support the medical device sector through measures such as large-scale equipment updates and the establishment of a unified national market for medical devices [5]. - The company has obtained numerous medical device registrations and certifications, including 414 medical device registration certificates and 483 CE certifications [12]. Market Trends - The IVD sector is expected to benefit from policies promoting domestic production and innovation, which may help local companies gain market share against international competitors [6]. - The trend towards centralized procurement and cost control in hospitals is pushing companies to optimize their cost structures and improve product differentiation [6]. Product Portfolio - DIRUI Medical's product lines include urine analysis, biochemical analysis, immunoassay, and coagulation analysis, among others, covering over 80% of testing items in clinical laboratories [10]. - The company’s products are designed to provide critical diagnostic information for disease prevention and treatment [10].

Core Viewpoint - Aibo Medical's stock price increased by 1.52% to 78.90 yuan as of August 25, 2025, with significant trading activity noted [1] Group 1: Stock Performance - Aibo Medical's stock opened at 77.72 yuan, reached a high of 79.11 yuan, and a low of 77.72 yuan, with a trading range of 1.79% on the same day [1] - The total trading volume for the day was 3.86 billion yuan [1] Group 2: Business Overview - Aibo Medical specializes in the research, production, and sales of ophthalmic medical devices, including artificial lenses and orthokeratology lenses [1] - The company operates in sectors such as medical devices and specialized innovation [1] Group 3: Trading Activity - On August 25, Aibo Medical experienced six block trades totaling 266,000 shares, amounting to 19.434 million yuan, with an average transaction price of 73.06 yuan, reflecting a discount of 7.40% compared to the closing price [1] - Institutional accounts purchased 58,000 shares, with a transaction value of 4.2375 million yuan [1] Group 4: Capital Flow - On the same day, Aibo Medical saw a net outflow of 1.6362 million yuan in main funds, while the net inflow over the past five days was 2.6767 million yuan [2]